Brain Trust Accelerator Fund
Brain Trust Accelerator Fund is a venture capital firm focused on impact investing in brain-related diseases. The firm specializes in translational stage investments that address the diagnosis and treatment of these diseases. With a strong track record, Fund I has generated top-tier returns, benefiting up to ten million patients and delivering significant charitable contributions. The firm leverages scientific advancements and market opportunities to invest in early-stage, translational research, aiming to transform pioneering research into meaningful clinical benefits.
Brain Trust Accelerator Fund
800 Airport Boulevard, Suite 508, Burlingame, CA 94010
Portfolio
Focused on novel therapeutics for improving memory deficits. Acquired by SYGNIS Pharma AG in 2008.
#Biotechnology
Develops the BrainScope One system for brain injury assessment. Launched in 2017, targeting various market segments.
#Neuro-technology
Focused on treatments for central nervous system diseases. Acquired by Allergan in 2016 after successful clinical trials.
#Pharmaceuticals
Developed targeted treatment approaches for neurological disorders. Acquired by Minnetronix in 2013.
#Medical Devices
Developed blood-based tests for neurodegenerative diseases. Acquired by Myriad Genetics in 2011.
#Molecular Diagnostics
Developing small molecules targeting CB2 receptors to reduce neuroinflammation. Completed Phase 1a clinical trial.
#Biotechnology
Key People
Managing Director